logo

For the Inventor, By the Inventor

Hasbrouck Heights, NJ, United States of America

Nymox Corporation

USPTO Granted Patents = 29

% Expired Patents = 34.5



Forward Citations = 272

Loading Chart...
Loading Chart...

8 inventors (with patents filed for the assignee):

goldMedal Paul A Averback (25 out of 41 patents)

silverMedal Jack Gemmell (5 out of 11 patents)

bronzeMedal Hossein A Ghanbari (3 out of 3 patents)

4.  Paul Averback (3 out of 3 patents)

5.  Iraj Beheshti (2 out of 2 patents)

6.  David Morse (2 out of 2 patents)

7.  Benjamin Wolozin (1 out of 3 patents)

8.  Celine Dupuis (1 out of 1 patent)

9.  Paul Averback (0 patent)


Core Competencies:
Fexapotide Triflutate
Prostate Cancer
LUTS
Benign Prostatic Hyperplasia
Tumor Treatment
Peptides
Alzheimer's Disease
Bacteriophages
Cellular Proliferation
Amyloid
Pharmaceutical Compositions

29 patents:

1. 12746268 - COMBINATION COMPOSITIONS FOR TREATING DISORDERS REQUIRING REMOVAL OR DESTRUCTION OF UNWANTED CELLULAR PROLIFERATIONS (2026-09-29),
2. 12329802 - Focal treatment of prostate cancer (2025-06-17),
3. 12090191 - Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS (2024-09-17),
4. 11628202 - Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia (2023-04-18),
5. 11331374 - Focal treatment of prostate cancer (2022-05-17),
6. 11298400 - Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS (2022-04-12),
7. 11278588 - Method of treating lower urinary tract symptoms with fexapotide triflutate (2022-03-22),
8. 11231421 - Methods of treating multifocal cancer (2022-01-25),
9. 10835538 - Method of treating benign prostatic hyperlasia with antibiotics (2020-11-17),
10. 10532081 - Method of ameliorating or preventing the worsening or the progression of symptoms of BPH (2020-01-14),
11. 10335453 - Compositions and methods for improving sexual function (2019-07-02),
12. 10183058 - Method of preventing or reducing the progression of prostate cancer (2019-01-22),
13. 10172910 - Method of preventing or reducing the incidence of acute urinary retention (2019-01-08),
14. 9243035 - Peptides effective in the treatment of conditions requiring the removal or destruction of cells (2016-01-26),
15. 8716247 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells (2014-05-06),
Company Overview
Nymox Corporation is a biopharmaceutical company based in Hasbrouck Heights, NJ, specializing in the development of innovative diagnostic and therapeutic products. The company focuses on addressing unmet medical needs, particularly in the fields of urology and neurology. Nymox is known for its proprietary technologies aimed at improving patient outcomes through advanced medical solutions, emphasizing research and development to bring new treatments to market. Its commitment to innovation positions it as a key player in the biopharmaceutical landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Nymox Corporation USPTO Patent Assignee Logo
29 Patents

#2 in Hasbrouck Heights, NJ

#466 in New Jersey

#11,631 in US

#22,570 in the World

Hasbrouck Heights, NJ (US)
Hasbrouck Heights, NJ, United States of America

Nymox Corporation

Forward Citations = 272

8 inventors:

goldMedal Paul A Averback (25 out of 41 patents)

silverMedal Jack Gemmell (5 out of 11 patents)

bronzeMedal Hossein A Ghanbari (3 out of 3 patents)

4.  Paul Averback (3 out of 3 patents)

5.  Iraj Beheshti (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nymox Corporation. Retrieved from https://idiyas.com/company/nymox

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…